On Tuesday, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was -5.60% drop from the session before settling in for the closing price of $18.57. A 52-week range for NAMS has been $15.19 – $27.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -28.76%. When this article was written, the company’s average yearly earnings per share was at 5.52%. With a float of $55.12 million, this company’s outstanding shares have now reached $92.17 million.
Let’s determine the extent of company efficiency that accounts for 29 employees. In terms of profitability, gross margin is 99.95%, operating margin of -495.6%, and the pretax margin is -534.64%.
NewAmsterdam Pharma Company NV (NAMS) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward NewAmsterdam Pharma Company NV stocks. The insider ownership of NewAmsterdam Pharma Company NV is 48.41%, while institutional ownership is 49.12%. The most recent insider transaction that took place on Jan 27 ’25, was worth 11,600,000. Before that another transaction happened on Jan 27 ’25, when Company’s Affiliate proposed sale 200,000 for $23.20, making the entire transaction worth $4,640,000.
NewAmsterdam Pharma Company NV (NAMS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.52% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
You can see what NewAmsterdam Pharma Company NV (NAMS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.61.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Looking closely at NewAmsterdam Pharma Company NV (NASDAQ: NAMS), its last 5-days average volume was 0.6 million, which is a drop from its year-to-date volume of 0.63 million. As of the previous 9 days, the stock’s Stochastic %D was 11.19%. Additionally, its Average True Range was 1.16.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 17.15%, which indicates a significant increase from 0.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.37% in the past 14 days, which was lower than the 77.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.14, while its 200-day Moving Average is $19.81. However, in the short run, NewAmsterdam Pharma Company NV’s stock first resistance to watch stands at $18.40. Second resistance stands at $19.27. The third major resistance level sits at $19.71. If the price goes on to break the first support level at $17.09, it is likely to go to the next support level at $16.65. Now, if the price goes above the second support level, the third support stands at $15.78.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
There are 92,386K outstanding shares of the company, which has a market capitalization of 1.87 billion. As of now, sales total 14,090 K while income totals -176,940 K. Its latest quarter income was 29,110 K while its last quarter net income were -16,650 K.
